Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CSPC Out-Licenses US/EU Rights to Two Generics for $201 Million

publication date: Dec 16, 2016
CSPC Pharma of Shijiazhuang announced two out-licensings from its generic drug portfolio that will bring in up to $201 million in milestones plus royalties. Through its subsidiary, CSPC Zhongqi Pharma, CSPC out-licensed US and EU rights for a development-stage complex injectible generic antibiotic to Teva Pharma for $100 million, and it licensed US rights for a complex generic oncology to Citron Pharma of New Jersey for $101 million in milestones. CSPC already sells the oncology product in China. More details....

Stock Symbols: (HK: 1093) (NYSE: TEVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital